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pen accessAbstract Background: This study was designed to evaluate the efﬁcacy of dexmedetomidine as a
hypotensive agent in comparison to sodium nitroprusside in scoliosis surgery.
Method: Forty patients ASA I or II aged (12–16) year scheduled for scoliosis surgery were ran-
domly assigned to receive either dexmedetomidine 1 lg/kg over 10 min before induction of anesthe-
sia followed by 0.2–0.5 lg/kg/h infusion during maintenance (DEX group) or sodium nitroprusside
1–10 lg/kg/min infusion after induction of anesthesia (SNP group) to maintain mean arterial blood
pressure between (60–65 mmHg). Mean arterial pressure (MAP), heart rate (HR), cardiac index
(CI), systemic vascular resistance index (SVRI) and stroke index (SI) were recorded. The two
groups were compared with reference to reversibility of hypotensive state, intraoperative blood loss
and transfusion requirement.
Results: Dexmedetomidine administration resulted in signiﬁcant reduction in MAP, HR and CI.
During the steady state hypotension SNP group showed signiﬁcant increase in HR and CI com-
pared to baseline and to DEX group (P< 0.05). SVRI was signiﬁcantly lower during controlled
hypotension in SNP group compared to DEX group (P< 0.001). Time to restoration of baseline
MAP was longer with DEX group (10.21 ± 1.52 min) than SNP group (4.87 ± 0.86 min)
(P< 0.001). Blood loss and transfusion requirement were signiﬁcantly lower in DEX group than(M.M. El-Gohary).
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306 M.M. El-Gohary, A.S. ArafaSNP group [1095.62 ± 128.9 6 ml versus 1287.50 ± 182.54 ml, P= 0.0013] and [855.42 ± 140.23
versus 1006.00 ± 154.66 ml, P= 0.0026], respectively.
Conclusion: Dexmedetomidine is a safe and effective drug for controlled hypotension in scoliosis
surgery. It may offer the signiﬁcant advantage of reducing blood loss and transfusion requirement.
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Scoliosis surgery is an extensive operative procedure that is
often accompanied by substantial blood loss which increases
the risks for the patient [1]. Factors inﬂuencing amount of
blood loss are the extent of dissection, the number of
vertebrae exposed for fusion, duration of surgery and surgical
technique [2].
Controlled hypotension is a commonly used technique to
limit blood loss and improve visualization of the operative ﬁeld
during spinal fusion surgery [3]. The characteristics of an ideal
hypotensive agent include easy administration, predictability
with anesthetic agents, and lack of toxic side effect while main-
taining adequate perfusion of the vital organs [4]. Many anes-
thetics and vasoactive drugs have been used successfully to
produce deliberate hypotension, including volatile anesthetics
[5], direct-acting vasodilators [6], autonomic ganglion-block-
ers, b-adrenergic receptor-blockers [7] and calcium channel
blockers [8].
Sodium nitroprusside (SNP) is one of the popular vasodila-
tors used to achieve induced hypotension because of its
attractive pharmacodynamics; rapid onset, rapid offset and
titrability. However, it may be associated with cyanide toxicity,
reﬂex tachycardia, rebound hypertension and platelet dysfunc-
tion [9].
Dexmedetomidine (DEX) is a potent highly selective a2
adrenergic agonist, possessing a differential speciﬁcity for
the a2:a1 receptors of 1620:1 [10]. It has sedative, analgesic
and anesthetic sparing effect, and sympatholytic properties
[11]. The central and peripheral sympatholytic action of
DEX is mediated by a2 adrenergic receptors [12] and is
manifested by dose-dependent decrease in arterial blood
pressure, heart rate, cardiac output and norepinephrine
release [11,13].
Despite several clinical trials that studied the effectiveness
of dexmedetomidine in reducing intraoperative bleeding in
adults [14–16], little is known about its effect as a sole hypoten-
sive agent in children and adolescents [17].
The present work was designed as a prospective and
andomized study to compare the efﬁcacy and safety of dex-
medetomidine versus sodium nitroprusside as a hypotensive
agent in adolescents undergoing posterior spinal fusion surgery
for repair of idiopathic scoliosis.
2. Methods
This study was conducted in Kasr El Aini teaching hospital
from December 2006 to April 2009. After approval of the local
ethical committee, written parental informed consents were
obtained. Forty patients 12–16 years of age, ASA I or II phys-
ical status undergoing corrective spinal surgery for idiopathic
scoliosis were enrolled in this prospective and randomized
study. Exclusion criteria included; respiratory or cardiacdysfunction, renal insufﬁciency, liver impairment, and bleeding
disorders.
Patients were randomly assigned according to computer-
generated randomization to receive either dexmedetomidine
(DEX group: n= 20) or sodium nitroprusside (SNP group:
n= 20) for controlled hypotension.
All patients were premedicated with IV midazolam
0.02 mg/kg after insertion of 22 G peripheral IV catheter.
Upon arrival to the operating room, another 20 G peripheral
IV catheter were inserted, one for administration of the study
drug and the other was used for induction of anesthesia. Stan-
dard monitors (Inﬁnity SC 8000, Dra¨ger medical system, Ave-
nue, Danvers, MA, USA) were applied and heart rate (HR),
noninvasive blood pressure and oxygen saturation (SPO2)
were continuously monitored. In addition, Cardiac Index
(CI), systemic vascular resistance index (SVRI) and stroke vol-
ume index (SI) were evaluated using a non-invasive impedance
cardiography (ICG) device (Bio.Z.Com, Cardiodynamics
international corporation, USA).
Before induction of anesthesia, patients allocated to (DEX)
group received loading dose of 1 lg/kg dexmedetomidine di-
luted in 10 ml 0.9% saline infused over 10 min followed by
continuous IV infusion of 0.2 lg/kg/h.
All patients received standard anesthetic technique using
2 lg/kg fentanyl and propofol 1 mg/kg supplemented, if neces-
sary by 0.2 mg/kg aliquots until loss of verbal response. The
required induction dose of propofol was recorded. Endotra-
cheal intubation was facilitated by the use of atracurium
0.5 mg/kg. Anesthesia was maintained with 0.5–1% end-tidal
isoﬂurane in 100% oxygen and fentanyl infusion 1 lg/kg/h.
Adequate muscle relaxation was maintained with incremental
bolus doses of 0.2 mg/kg atracurium when indicated by periph-
eral nerve stimulation. Controlled ventilation was adjusted to
maintain normocapnia (30–35 mmHg).
After induction of anesthesia, another large bore I.V cath-
eter was inserted for ﬂuids and blood transfusion. 22 G radial
artery catheter was inserted for continuous measurement of
arterial blood pressure. Esophageal temperature probe was ap-
plied and normothermia was maintained with a heating mat-
tress and infusion of warm ﬂuids. Foley’s catheter was
inserted to monitor urine output.
All patients were placed prone on a Relton frame with the
abdomen hanging free where eyes, airway and pressure points
were checked and protected.
After positioning patients allocated to (SNP) group re-
ceived 1 lg/kg/min continuous sodium nitroprusside infusion
(0.01%). The infusion rate of both studied drugs was gradually
increased to achieve target mean arterial blood pressure
(MAP) between 60–65 mmHg prior to skin incision.
The maximum allowed infusion rate was o.5 lg/kg/h in
DEX group and 10 lg/kg/min in SNP group. Patient reached
the maximum dose without obtaining the target MAP were ex-
cluded from the study and added therapy was given.
Dexmedetomidine as a hypotensive agent: Efﬁcacy and hemodynamic response during spinal surgery 307The same surgical team performed all operations to ensure
consistency of surgical technique and duration of surgery.
During the course of induced hypotension, reﬂex tachycar-
dia deﬁned as persistent increase in HR exceeding 110 bpm for
more than 10 min, was treated by a bolus dose of esmolol
0.5 mg/kg. If the MAP decreased below 60 mmHg, gradual de-
crease of the studied drug started together with ephedrine
shots (10 mg) and ﬂuid bolus, progressed to stopping the study
drug if needed and those patients were excluded from the
study. Bradycardia (HR <60 beat/min) was treated with
10 lg/kg atropine intravenously.
Fluid therapy included maintenance plus deﬁcit ﬂuids re-
placed over the ﬁrst three to 4 h of the procedure and third
space losses which were replaced by 6 ml/kg/h. Intraoperative
blood transfusions were given to maintain the level of hemo-
globin (Hb) equal to or greater than 10 g/dl.
Hypotensive infusions were stopped after placement of
rods, and reversibility of the hypotensive state (time required
to restore the MAP to baseline measurement after discontinu-
ation of the study drug) was recorded. At the conclusion of
surgery, fentanyl infusion was stopped and residual neuromus-
cular block was antagonized with neostigmine (0.05 mg/kg)
and atropine (0.01 mg/kg). After extubation and full recovery,
patients were transferred to the postanesthetic care unit
(PACU) to be observed for 1 h where time to ﬁrst analgesic
rescue was recorded.
MAP, HR, CI, SI and SVRI were recorded at the following
times: upon arrival to the operating room (T0), immediately
before induction of anesthesia (after loading dose in DEX
group) (T1), after induction of anesthesia (T2), 15 min after
positioning (steady state hypotension) (T3), 5 min after stop-
ping hypotensive drug (T4), 20 min after stopping hypotensive
drug (T5).
Both groups were compared with reference to intraopera-
tive blood loss, blood transfusion requirement and number
of patients who required esmolol supplementation.
Based on the ﬁndings of a pilot study we had performed be-
fore conduct of the main study, we observed a standardized ef-
fect size (d) of 0.98 in blood loss which represented a between-
group percentage difference of 16%. By adopting a statistical
signiﬁcance of 95%, a statistical power of 80% (a= 0.05,
b= 0.20) and a group allocation ratio of 1:1, sample size cal-
culation determined that 18 subjects are required in each of
both study groups to detect difference 16% or more in blood
loss. Power calculations was performed using computer pro-
gram G*Power 3 for Windows (Franz Faul, Universita¨t Kiel,
Germany).Table 1 Demographic and operative data [mean (SD) or ratio].
SNP group (n= 20)
Age (year) 13.45 (1.47)
Weight (kg) 48.25 (5.61)
Height (cm) 143.25 (7.89)
Sex (M/F) 8/12
Duration of surgery (h) 4.32 ± 0.50
Blood loss (ml) 1287.50 ± 182.54
Blood transfusion (ml) 1006.00 ± 154.66
Levels fused 9.4 ± 1
SNP group = sodium nitroprusside group, DEX group = dexmedetomid3. Statistical methods
Data was analyzed using SPSSwin statistical package version
15. Numerical data was expressed as mean ± standard devia-
tion. Comparison between the two groups was done using
parametric or non-parametric t-test. Intragroup comparison
relative to baseline were performed using repeated measure
analysis of variance (ANOVA) with post hoc Dunnet’s test if
ANOVA results were signiﬁcant. P-value <0.05 was consid-
ered signiﬁcant.4. Results
Fifty two patients were assessed for study eligibility, seven pa-
tients failed to meet the inclusion criteria and ﬁve patients,
their parents refused to sign the consent form. The remaining
forty patients who fulﬁlled the study criteria were enrolled in
this study. All patients were able to complete the entire study
and their data were included in the ﬁnal analysis.
Patient demographic data, the number of levels fused and
the duration of surgery were comparable between the two
groups (Table 1).
The propofol dose required for induction of anesthesia was
signiﬁcantly lower in DEX group than in SNP group
[(1.57 ± 0.27 mg/kg) versus (2.28 ± 0.44 mg/kg)], respectively
(P< 0.001).
Baseline values of MAP and HR were comparable in both
groups. Dexmedetomidine administration in DEX group re-
sulted in signiﬁcant reduction of MAP from T1 to T4 com-
pared to baseline value. In SNP group, MAP was
signiﬁcantly lower than baseline only at T3 (P< 0.05). At
T3 both groups reach the desired MAP (60–65 mmHg) with
no intergroup signiﬁcant difference while at T4 DEX group
showed signiﬁcantly lower MAP than SNP group (P< 0.05)
(Fig. 1).
Heart rate decreased signiﬁcantly relative to baseline after
administration of loading dose (T1) in DEX group and re-
mained so until T4. However, in the SNP group there was sig-
niﬁcant increase in HR compared to baseline only at T3.
Compared to SNP group, HR in the DEX group was signiﬁ-
cantly lower at T3 and T4 (P< 0.01) (Fig. 2).
In DEX group CI was signiﬁcantly lower compared to
baseline from T1 till T4. Conversery, CI in the SNP
group was comparable to baseline at all time intervals
except at T3, where it was signiﬁcantly higher (P< 0.05)
(Fig. 3).DEX group (n= 20) P value
12.9 (1.15) 0.195
46.92 (7.60) 0.53
146.11 (6.73) 0.225
7/13
4.11 (0.42) 0.159
1095.62 ± 168.96 0.0013
855.42 ± 140.23 0.0026
10 ± 1.2 0.094
ine group.
Figure 2 Perioperative heart rate. Data points are means and
bars are SD. SNP group = sodium nitroprusside group, DEX
group = dexmedetomidine group. T0 = upon arrival to the
operating room, T1 = immediately before induction, T2 = after
induction of anesthesia, T3 = during steady state hypotension,
T4 = 5 min after stopping the hypotensive agent, T5 = 20 min
after stopping the hypotensive agent. * = P< 0.05 relative to
baseline value. = P< 0.01 relative to the SNP group.
Figure 3 Perioperative cardiac index. Data points are means and
bars are SD. SNP group = sodium nitroprusside group, DEX
group = dexmedetomidine group. T0 = upon arrival to the
operating room, T1 = immediately before induction, T2 = after
induction of anesthesia, T3 = during steady state hypotension,
T4 = 5 min after stopping the hypotensive agent, T5 = 20 min
after stopping the hypotensive agent. * = P< 0.05 relative to
baseline value. = P< 0.001 relative to the SNP group.
Table 2 Perioperative stroke index (ml/m2) [mean (SD)].
SNP group (n= 20) DEX group (n= 20)
T0 39.85 ± 3.03 38.75 ± 2.53
T1 39.60 ± 3.07 38.50 ± 2.24
T2 39.40 ± 2.89 38.60 ± 2.35
T3 39.05 ± 2.76 38.35 ± 2.01
T4 39.45 ± 2.54 38.70 ± 1.95
T5 39.20 ± 2.33 38.80 ± 1.91
SNP group = sodium nitroprusside group, DEX group = dex-
medetomidine group. T0 = upon arrival to the operating room,
T1 = immediately before induction, T2 = after induction of
anesthesia, T3 = during steady state hypotension, T4 = 5 min
after stopping the hypotensive agent, T5 = 20 min after stopping
the hypotensive agent.
Figure 1 Perioperative mean arterial pressure. Data points are
means and bars are SD. SNP group = sodium nitroprusside
group, DEX group = dexmedetomidine group. T0 = upon arri-
val to the operating room, T1 = immediately before induction,
T2 = after induction of anesthesia, T3 = during steady state
hypotension, T4 = 5 min after stopping the hypotensive agent,
T5 = 20 min after stopping the hypotensive agent. * = P< 0.05
relative to baseline value. = P< 0.05 relative to the SNP group.
Figure 4 Perioperative systemic vascular resistance index. Data
points are means and bars are SD. SNP group = sodium nitro-
prusside group, DEX group = dexmedetomidine group. T0 =
upon arrival to the operating room, T1 = immediately before
induction, T2 = after induction of anesthesia, T3 = during steady
state hypotension,T4 = 5 min after stopping thehypotensive agent,
T5 = 20 min after stopping the hypotensive agent. * = P< 0.05
relative to baseline value. = P< 0.001 relative to the SNP group.
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baseline at T2, T3, T4 (P< 0.05), however values in SNP
group was signiﬁcantly lower compared to DEX group during
steady state hypotension (P< 0.001) (Fig. 4).
There were no signiﬁcant intergroup or intragroup differ-
ences in stroke index values (Table 2).
Esmolol administration was necessary in 12 out of 20
(60%) patient in SNP group in comparison, no patient in
DEX group received esmolol therapy. Withdrawal of the
hypotensive agent was not associated with rebound hyperten-
sion in any of the patients included in the study.
Reversibility of hypotensive state as deﬁned by the protocol
was signiﬁcantly shorter in SNP group compared to the DEX
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tively (P< 0.001).
There was a statistically signiﬁcant increase in the amount
of blood loss and blood transfusion requirement in SNP group
compared to DEX group (P< 0.01) (Table 1).
Time recorded to ﬁrst analgesic requirement was signiﬁ-
cantly shorter in SNP group versus DEX group
[(36.16 ± 7.20 min) versus (53.75 ± 6.15 min)], respectively
(P< 0.001).
5. Discussion
Anesthesia for correction of scoliosis in children is a challenge
because of the frequent co-morbidities of these patients and
the extensive nature of the procedure itself [18]. Scoliosis cor-
rection may be associated with major blood loss (>50% of
blood volume) and development of coagulopathy, which is
both dilutional and consumptive [19].
In this prospective and randomized study, dexmedetomi-
dine in comparison to sodium nitroprusside was successful at
achieving deliberate hypotension. It provided less blood loss
and blood transfusion requirement during spinal fusion sur-
gery in adolescents with idiopathic scoliosis. In addition dex-
medetomidine decreased the induction dose of propofol and
prolonged the time to ﬁrst analgesic rescue.
The hypnotic and sedative actions of dexmedetomidine are
thought to be mediated primarily by postsynaptic a2-adrenrgic
receptors [20]. In the current study, the induction dose of pro-
pofol was signiﬁcantly lower in DEX group than in SNP
group. This effect coinciding with the result of other investiga-
tors, Peden et al. found that dexmedetomidine caused a reduc-
tion in the overall concentration and dose of propofol required
to produce loss of consciousness [21].
Controlled hypotension has been widely advocated to re-
duce blood loss, yet it may be associated with increased risk
of neurological deﬁcit because of reduced spinal cord perfu-
sion, specially if this is compromised by distraction [22]. This
is why we used a more conservative control of MAP (60–
65 mmHg) which was effectively reached in both groups before
skin incision. Patients who were treated with dexmedetomidine
10 min before induction of anesthesia had a signiﬁcant de-
crease in MAP, HR and CI after administration the loading
dose without signiﬁcant changes in SVRI or SI.
This dexmedetomidine-induced haemodynamic proﬁle can
be attributed to the known sympatholytic effects of a2-ago-
nists. The a2-receptors are involved in regulating the auto-
nomic and cardiovascular systems. Alpha-2 receptors are
located on blood vessels, where they mediate vasoconstriction,
and on sympathetic terminals, where they inhibit norepineph-
rine release [23]. At lower doses, the dominant action of a2-
agonist is sympatholysis [24].
There are several well-documented mechanisms for this
activity including, the drug actions on several brain stem and
medullary nuclei (nucleus tractus solitarus and the lateral retic-
ular nucleus), and the hypothalamus to decrease sympathetic
nervous system activity and inhibit norepinephrine release at
neuroeffector junction [25]. The activation of central receptors
leads to reduction of tonic level of sympathetic outﬂow, and an
augmentation of cardiac vagal activity [26]. This can result in a
decrease of HR and cardiac output (CO).
This agree with what was reported by Ebert et al. [27] who
determined the response to increasing plasma concentration ofdexmedetomidine in humans and stated that lower plasma dex-
medetomidine concentration resulted in decreases in MAP,
HR and CI without changes in stroke volume, pulmonary or
systemic vascular resistance. Kallio et al. [28] reported a
23% decrease in CO after IV administration of 100 lg sin-
gle-dose dexmedetomidine. Basar et al. [29] investigated the ef-
fect of a single dose of dexmedetomidine 0.5 lg/kg
administered 10 min before induction of anesthesia and re-
ported 27% decrease in CI, signiﬁcant reduction in MAP
and HR without changes in SVI.
Tobias and Berkenbosch [17] when used dexmedetomidine
for controlled hypotension in a case of pediatric patient under-
going spinal fusion surgery, the target MAP (55–60) was suc-
cessfully achieved with restoration of baseline values 7 min
after discontinuation. The efﬁcacy of dexmedetomidine in con-
trolled hypotension was previously reported in adults [14–16].
The hypotensive effect of SNP is the result of both primary
direct vasodilator effects on vascular smooth muscles, which
tends to lower blood pressure and decrease systemic vascular
resistance as well as compensatory homeostatic reﬂex [30]. This
homeostatic reﬂex which includes tachycardia and increased
CO is thought to be related to reﬂex sympathetic stimulation
that result in the release of endogenous catecholamines and
activation of renin angiotensin system [31]. This was evident
in SNP group as signiﬁcant increase in HR and CI during
the period of steady sate hypotension with signiﬁcant decrease
in SVRI compared both to baseline and to the other group.
Sodium nitroprusside causes vascular relaxation via pro-
duction of nitric oxide which has a half life of 0.1 s [32], while
dexmedetomidine is highly speciﬁc alpha 2 agonist, removal of
dexmedetomidine would not result in restoration of blood
pressure until the drug diffused out of the receptor site [20].
This could explain the signiﬁcant short time to restoration of
MAP in SNP group compared to DEX group in the present
study. Although rapid restoration of blood pressure in SNP
group is beneﬁcial both to patient and surgeon yet this gradual
restoration could also have the advantage of limiting the
occurrence of rebound hypertension and giving time for clot
formation thus reducing immediate postoperative bleeding.
The key outcomes used to evaluate the efﬁcacy of a tech-
nique for controlled hypotension are the estimated intraopera-
tive blood loss and need for blood transfusion [33]. In the
present work, intraoperative blood loss and blood transfusion
requirement were signiﬁcantly lower in DEX group than in
SNP group. The efﬁcacy of dexmedetomidine in providing bet-
ter surgical ﬁeld and less blood loss during controlled hypoten-
sion was previously reported in adult [14–16]. In consistency
with our results, Hersey et al. [34] noted signiﬁcant increase
in blood loss in patients who received SNP compared to those
who received nicardipinie for controlled hypotension during
spinal fusion surgery for idiopathic scoliosis.
Blood loss in scoliosis is highly dependent on the degree of
venous congestion. Sodium nitroprusside is a peripheral vaso-
dilator agent with pronounced venous effect, dilatation of the
venous plexus around the vertebral bodies may have contrib-
uted to increased blood loss when SNP used for controlled
hypotension during scoliosis surgery [33]. The relationship
between venous congestion and blood loss had been previously
reported by Relton and Hall [35]. As the target MAP
(60–65 mmHg) was achieved in both groups of the present
study, it is conceivable that some degree of venous congestion
occurred in the SNP group resulted in increased blood loss.
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blood loss during induced hypotensive anesthesia. Knight
et al. [36] noted that; for scoliosis surgery, blood loss correlated
with ventricular stroke work index calculated from SVR, CO
and HR. However, Sivarajan et al. [37] when used SNP for
controlled hypotension found that despite signiﬁcant increase
in CO and HR there was no signiﬁcant increase in blood loss.
In spite of the beneﬁts of maintaining a constant CI in pediat-
ric age group yet it may have contributed to increased blood
loss in SNP group compared with that in DEX group in the
present study.
Although the organic nitrate vasodilators inhibit platelet
function via production of nitric oxide [38], it is unclear
whether this is a contributing factor in the increased blood loss
for SNP group in this study.
The prolonged postoperative analgesia demonstrated in
DEX group in the present study is in accordance with Gurbet
et al. [39] who stated that intraoperative infusion of dexmede-
tomidine reduces perioperative analgesic requirement.
In conclusion, this study showed that dexmedetomidine is
an effective and safe agent for controlled hypotension in ado-
lescents undergoing spinal fusion surgery for idiopathic scolio-
sis. Compared with sodium nitroprusside, it offers the
advantage of reduced blood loss. In addition, it posses inher-
ent anesthetic and analgesic effect.
Further studies are required to evaluate the intraoperative
analgesic effect of dexmedetomidine during scoliosis surgery.
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